05.01.08
TSI Health Sciences, Missoula, MT, has secured a U.S. patent for its Promilin ingredient, allowing the company to continue to develop the market for this proprietary product, which promotes healthy glucose and insulin utilization. A key provision of U.S. patent 7,338,675, entitled “Fenugreek seed bio-active compositions and methods for extracting same,” involves providing novel compositions and methods for the extraction and separation of bioactive compounds/compositions of 4-hydroxyisoleucine from fenugreek seeds. This unique composition can work either synergistically with insulin, or independently to stimulate GT-4 receptors located on skeletal muscles, to stimulate glucose transport proteins and facilitate the transport of glucose into muscle cells.